SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Tomoyuki Takashima, Hirayuki Enomoto, Toshiaki Ninomiya, Soo Ryang Kim, Hiroaki Okushin, Masahiko Sugano, Susumu Imoto, Yoshihiko Yano, Teruji Ooka, Yasushi Seo, Hiroshi Kasugai, Akira Muramatsu, Hisato Jomura, Soji Shimomura, Michiko Shindo, Hideji Nakamura, Nobuhiro Aizawa, Yoshinori Iwata, Masaki Saito, Hiroyasu Imanishi, Hiroko Iijma, Shuhei Nishiguchi, Hepatitis C virus relapse was suppressed by long-term self-injection of low-dose interferon in patients with chronic hepatitis C after pegylated interferon plus ribavirin treatment, Hepatology Research, 2014, 44, 6
  2. 2
    Kun-Ming Chung, Tsu-Ming Chien, Shih-Sung Chuang, Hung-Chang Wu, Ming-Jen Sheu, Ching-Yih Lin, Hsing-Tao Kuo, High pre-operative serum aminotransferase levels predict local recurrence after curative resection of hepatocellular carcinoma, Advances in Digestive Medicine, 2014, 1, 1, 14

    CrossRef

  3. 3
    Masaya Sato, Naoya Kato, Ryosuke Tateishi, Ryosuke Muroyama, Norie Kowatari, Wenwen Li, Kaku Goto, Motoyuki Otsuka, Shuichiro Shiina, Haruhiko Yoshida, Masao Omata, Kazuhiko Koike, Impact of PNPLA3 polymorphisms on the development of hepatocellular carcinoma in patients with chronic hepatitis C virus infection, Hepatology Research, 2014, 44, 9
  4. 4
    Hiroaki Okushin, Takeharu Yamamoto, Hiroshi Kishida, Kazuhiko Morii, Koichi Uesaka, Indices of initial hepatitis C virus RNA reduction rate to predict efficacy of interferon-beta followed by peginterferon plus ribavirin for genotype 1b high viral load, Hepatology Research, 2014, 44, 7
  5. 5
    Masaru Enomoto, Akihiro Tamori, Yoshiki Murakami, Norifumi Kawada, Interferon-α/β for treatment of chronic hepatitis C infection in the era of direct-acting antiviral agents, Hepatology Research, 2014, 44, 4
  6. 6
    Toshifumi Tada, Takashi Kumada, Hidenori Toyoda, Seiki Kiriyama, Makoto Tanikawa, Yasuhiro Hisanaga, Akira Kanamori, Shusuke Kitabatake, Takuro Niinomi, Takanori Ito, Ryohei Hasegawa, Yusuke Ando, Kenta Yamamoto, Tatsuya Tanaka, Oral supplementation with branched-chain amino acid granules prevents hepatocarcinogenesis in patients with hepatitis C-related cirrhosis: A propensity score analysis, Hepatology Research, 2014, 44, 3
  7. 7
    Yoshihiko Tachi, Takanori Hirai, Akihiro Miyata, Kei Ohara, Tadashi Iida, Youji Ishizu, Takashi Honda, Teiji Kuzuya, Kazuhiko Hayashi, Masatoshi Ishigami, Hidemi Goto, Progressive fibrosis significantly correlates with hepatocellular carcinoma in patients with a sustained virological response, Hepatology Research, 2014, 44, 9
  8. 8
    Yutaka Yasui, Atsushi Kudo, Masayuki Kurosaki, Shuya Matsuda, Masaru Muraoka, Nobuharu Tamaki, Shoko Suzuki, Takanori Hosokawa, Ken Ueda, Kotaro Matsunaga, Hiroyuki Nakanishi, Kaoru Tsuchiya, Jun Itakura, Yuka Takahashi, Shinji Tanaka, Yasuhiro Asahina, Nobuyuki Enomoto, Shigeki Arii, Namiki Izumi, Reduced Organic Anion Transporter Expression Is a Risk Factor for Hepatocellular Carcinoma in Chronic Hepatitis C Patients: A Propensity Score Matching Study, Oncology, 2014, 86, 1, 53

    CrossRef

  9. 9
    N. Harada, N. Hiramatsu, T. Oze, N. Morishita, R. Yamada, H. Hikita, M. Miyazaki, T. Yakushijin, T. Miyagi, Y. Yoshida, T. Tatsumi, T. Kanto, A. Kasahara, M. Oshita, E. Mita, H. Hagiwara, Y. Inui, K. Katayama, S. Tamura, H. Yoshihara, Y. Imai, A. Inoue, N. Hayashi, T. Takehara, Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin, Journal of Viral Hepatitis, 2014, 21, 5
  10. 10
    Masanori Atsukawa, Akihito Tsubota, Noritomo Shimada, Chisa Kondo, Norio Itokawa, Ai Nakagawa, Satomi Hashimoto, Takeshi Fukuda, Yoko Matsushita, Yoshiyuki Narahara, Katsuhiko Iwakiri, Katsuhisa Nakatsuka, Chiaki Kawamoto, Choitsu Sakamoto, Serum 25-hydroxyvitamin D3 levels affect treatment outcome in pegylated interferon/ribavirin combination therapy for compensated cirrhotic patients with hepatitis C virus genotype 1b and high viral load, Hepatology Research, 2014, 44, 9
  11. 11
    Sohji Nishina, Junko Kurihara, Toshiaki Noriyasu, Tatsuya Itoshima, Kazuhide Yamamoto, Junko Tanaka, Keisuke Hino, A follow-up survey of hepatitis virus carriers after notification of their infection in Okayama prefecture, Kanzo, 2013, 54, 1, 84

    CrossRef

  12. 12
    Tasuku Hara, Norio Akuta, Fumitaka Suzuki, Hitomi Sezaki, Yoshiyuki Suzuki, Tetsuya Hosaka, Masahiro Kobayashi, Mariko Kobayashi, Satoshi Saitoh, Hiromitsu Kumada, A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C, Journal of Medical Virology, 2013, 85, 10
  13. 13
    S. Aleman, N. Rahbin, O. Weiland, L. Davidsdottir, M. Hedenstierna, N. Rose, H. Verbaan, P. Stal, T. Carlsson, H. Norrgren, A. Ekbom, F. Granath, R. Hultcrantz, A Risk for Hepatocellular Carcinoma Persists Long-term After Sustained Virologic Response in Patients With Hepatitis C-Associated Liver Cirrhosis, Clinical Infectious Diseases, 2013, 57, 2, 230

    CrossRef

  14. 14
    Yuya Seko, Norio Akuta, Fumitaka Suzuki, Yusuke Kawamura, Hitomi Sezaki, Yoshiyuki Suzuki, Tetsuya Hosaka, Masahiro Kobayashi, Mariko Kobayashi, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada, Amino Acid Substitutions in the Hepatitis C Virus Core Region and Lipid Metabolism Are Associated with Hepatocarcinogenesis in Nonresponders to Interferon plus Ribavirin Combination Therapy, Intervirology, 2013, 56, 1, 13

    CrossRef

  15. 15
    Takashi Honda, Yoshiaki Katano, Teiji Kuzuya, Kazuhiko Hayashi, Masatoshi Ishigami, Akihiro Itoh, Yoshiki Hirooka, Isao Nakano, Tetsuya Ishikawa, Hidenori Toyoda, Takashi Kumada, Koji Yamamoto, Tadashi Matsushita, Tetsuhito Kojima, Junki Takamatsu, Hidemi Goto, Comparison of the efficacy of ribavirin plus peginterferon alfa-2b for chronic hepatitis C infection in patients with and without coagulation disorders, Journal of Medical Virology, 2013, 85, 2
  16. 16
    Yasuji Arase, Mariko Kobayashi, Fumitaka Suzuki, Yoshiyuki Suzuki, Yusuke Kawamura, Norio Akuta, Masahiro Kobayashi, Hitomi Sezaki, Satoshi Saito, Tetsuya Hosaka, Kenji Ikeda, Hiromitsu Kumada, Tetsuro Kobayashi, Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C, Hepatology, 2013, 57, 3
  17. 17
    Norio Akuta, Fumitaka Suzuki, Yuya Seko, Yusuke Kawamura, Hitomi Sezaki, Yoshiyuki Suzuki, Tetsuya Hosaka, Masahiro Kobayashi, Mariko Kobayashi, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada, Efficacy and Anticarcinogenic Activity of Ribavirin Combination Therapy for Hepatitis C Virus-Related Compensated Cirrhosis, Intervirology, 2013, 56, 1, 37

    CrossRef

  18. You have free access to this content18
    C.-C. Hu, C.-L. Lin, Y.-L. Kuo, C.-H. Chien, S.-W. Chen, C.-L. Yen, C.-Y. Lin, R.-N. Chien, Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C, Alimentary Pharmacology & Therapeutics, 2013, 37, 1
  19. 19
    Masanori Atsukawa, Akihito Tsubota, Noritomo Shimada, Chisa Kondo, Norio Itokawa, Ai Nakagawa, Satomi Hashimoto, Takeshi Fukuda, Yoko Matsushita, Hideko Kidokoro, Yoshiyuki Narahara, Katsuhisa Nakatsuka, Katsuhiko Iwakiri, Chiaki Kawamoto, Choitsu Sakamoto, Efficacy of Alfacalcidol on PEG-IFN/ Ribavirin Combination Therapy for Elderly Patients With Chronic Hepatitis C: A Pilot Study, Hepatitis Monthly, 2013, 13, 12

    CrossRef

  20. 20
    Mohammad Asim, Manash Pratim Sarma, Premashis Kar, Etiological and molecular profile of hepatocellular cancer from India, International Journal of Cancer, 2013, 133, 2
  21. You have free access to this content21
    Guidelines for the Management of Hepatitis C Virus Infection, Hepatology Research, 2013, 43, 1
  22. 22
    Naoki Yamashita, Aritsune Ohho, Akihiro Yamasaki, Miho Kurokawa, Kazuhiro Kotoh, Eiji Kajiwara, Hepatocarcinogenesis in chronic hepatitis C patients achieving a sustained virological response to interferon: significance of lifelong periodic cancer screening for improving outcomes, Journal of Gastroenterology, 2013,

    CrossRef

  23. 23
    Alessio Aghemo, Massimo Colombo, Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside, Seminars in Immunopathology, 2013, 35, 1, 111

    CrossRef

  24. 24
    Namiki Izumi, Yasuhiro Asahina, Masayuki Kurosaki, Gotaro Yamada, Tsutomu Kawai, Eiji Kajiwara, Yukishige Okamura, Takayuki Takeuchi, Osamu Yokosuka, Kazuya Kariyama, Joji Toyoda, Mie Inao, Eiji Tanaka, Hisataka Moriwaki, Hiroshi Adachi, Shinji Katsushima, Masatoshi Kudo, Kouichi Takaguchi, Yoichi Hiasa, Kazuaki Chayama, Hiroshi Yatsuhashi, Makoto Oketani, Hiromitsu Kumada, Inhibition of hepatocellular carcinoma by PegIFNα-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study, Journal of Gastroenterology, 2013, 48, 3, 382

    CrossRef

  25. 25
    Ahmed El-Shamy, Michiko Shindo, Ikuo Shoji, Lin Deng, Tadao Okuno, Hak Hotta, Polymorphisms of the core, NS3, and NS5A proteins of hepatitis C virus genotype 1b associate With development of hepatocellular carcinoma, Hepatology, 2013, 58, 2
  26. 26
    Yuko Nagaoki, Hiroshi Aikata, Tomoki Kobayashi, Takayuki Fukuhara, Keiichi Masaki, Mio Tanaka, Noriaki Naeshiro, Takashi Nakahara, Yohji Honda, Daisuke Miyaki, Tomokazu Kawaoka, Shintaro Takaki, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Hideyuki Hyogo, Yoshiiku Kawakami, Shoichi Takahashi, Hidenori Ochi, Kazuaki Chayama, Risk factors for the exacerbation of esophageal varices or portosystemic encephalopathy after sustained virological response with IFN therapy for HCV-related compensated cirrhosis, Journal of Gastroenterology, 2013, 48, 7, 847

    CrossRef

  27. 27
    Danbi Lee, Young-Hwa Chung, Jeong A. Kim, Won Hyung Park, Young-Joo Jin, Ju Hyun Shim, Soo Hyung Ryu, Myoung Kuk Jang, Eunsil Yu,, Young Joo Lee, Safety and efficacy of adjuvant pegylated interferon therapy for metastatic tumor antigen 1-positive hepatocellular carcinoma, Cancer, 2013, 119, 12
  28. 28
    Yasuhiro Asahina, Kaoru Tsuchiya, Takashi Nishimura, Masaru Muraoka, Yuichiro Suzuki, Nobuharu Tamaki, Yutaka Yasui, Takanori Hosokawa, Ken Ueda, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Masayuki Kurosaki, Nobuyuki Enomoto, Mina Nakagawa, Sei Kakinuma, Mamoru Watanabe, Namiki Izumi, α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C, Hepatology, 2013, 58, 4
  29. 29
    Vivek Kohli, Ashish Singhal, Lenzi Elliott, Sajid Jalil, Antiviral therapy for recurrent hepatitis C reduces recurrence of hepatocellular carcinoma following liver transplantation, Transplant International, 2012, 25, 2
  30. 30
    Necati Örmeci, Hakan Erdem, Basic answers to complicated questions for the course of chronic hepatitis C treatment, Expert Review of Gastroenterology & Hepatology, 2012, 6, 3, 371

    CrossRef

  31. 31
    Norio Akuta, Fumitaka Suzuki, Yuya Seko, Yusuke Kawamura, Hitomi Sezaki, Yoshiyuki Suzuki, Tetsuya Hosaka, Masahiro Kobayashi, Tasuku Hara, Mariko Kobayashi, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada, Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis, Hepatology, 2012, 56, 6
  32. 32
    Masaya Saito, Yasushi Seo, Yoshihiko Yano, Akira Miki, Yukiko Morinaga, Tomoo Itoh, Masaru Yoshida, Takeshi Azuma, Development of a hepatocellular carcinoma in a chronic hepatitis C patient 18 years after achieving a sustained virological response to interferon therapy: case report and literature review, Clinical Journal of Gastroenterology, 2012, 5, 2, 119

    CrossRef

  33. 33
    Yasuji Arase, Mariko Kobayashi, Fumitaka Suzuki, Yoshiyuki Suzuki, Yusuke Kawamura, Norio Akuta, Norihiro Imai, Masahiro Kobayashi, Hitomi Sezaki, Naoki Matsumoto, Satoshi Saito, Tetsuya Hosaka, Kenji Ikeda, Hiromitsu Kumada, Yuki Ohmoto, Kazuhisa Amakawa, Shiun Dong Hsieh, Kyoko Ogawa, Maho Tanabe, Hiroshi Tsuji, Tetsuro Kobayashi, Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients, Hepatology Research, 2012, 42, 3
  34. 34
    Hirotoshi Ebinuma, Hidetsugu Saito, Shinichiro Tada, Nobuhiro Nakamoto, Tazuko Ohishi, Satoshi Tsunematsu, Naoki Kumagai, Kanji Tsuchimoto, Nobuhiro Tsukada, Yasutaka Inagaki, Yoshinori Horie, Masahiko Takahashi, Kazuhiro Atsukawa, Yukishige Okamura, Takanori Kanai, Toshifumi Hibi, Disadvantages of peginterferon and ribavirin treatment in older patients with chronic hepatitis C: an analysis using the propensity score, Hepatology International, 2012, 6, 4, 744

    CrossRef

  35. 35
    Eiji Kajiwara, Aritune Ooho, Naoki Yamashita, Effectiveness of biweekly low-dosage peginterferon treatment on the improvement of serum alanine aminotransferase and α-fetoprotein levels, Hepatology Research, 2012, 42, 3
  36. 36
    Kazumi Yamasaki, Mayumi Tomohiro, Yumiko Nagao, Michio Sata, Toshiaki Shimoda, Kazuhiro Hirase, Satoshi Shirahama, Effects and Outcomes of Interferon Treatment in Japanese Hepatitis C Patients, BMC Gastroenterology, 2012, 12, 1, 139

    CrossRef

  37. 37
    Junko Matsuo, Masaaki Mizui, Hajime Okita, Keiko Katayama, Shiomi Aimitsu, Tatsuro Sakata, Makoto Obayashi, Toshio Nakanishi, Kazuaki Chayama, Yuzo Miyakawa, Hiroshi Yoshizawa, Junko Tanaka, Follow up of the 987 blood donors found with hepatitis C virus infection over 9–18 years, Hepatology Research, 2012, 42, 7
  38. You have full text access to this Open Access content38
    Daiki Miki, Hidenori Ochi, C. Nelson Hayes, Hiroshi Aikata, Kazuaki Chayama, Hepatocellular carcinoma: Towards personalized medicine, Cancer Science, 2012, 103, 5
  39. 39
    Yoshisato Tanimoto, Hirotaka Tashiro, Hiroshi Aikata, Hironobu Amano, Akihiko Oshita, Tsuyoshi Kobayashi, Shintaro Kuroda, Hirofumi Tazawa, Shoichi Takahashi, Toshiyuki Itamoto, Kazuaki Chayama, Hideki Ohdan, Impact of Pegylated Interferon Therapy on Outcomes of Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma After Curative Hepatic Resection, Annals of Surgical Oncology, 2012, 19, 2, 418

    CrossRef

  40. 40
    Tomohiko Akahoshi, Morimasa Tomikawa, Hirofumi Kawanaka, Norihiro Furusyo, Nao Kinjo, Norifumi Tsutsumi, Yoshihiro Nagao, Jun Hayashi, Makoto Hashizume, Yoshihiko Maehara, Laparoscopic splenectomy with interferon therapy in 100 hepatitis-C-virus-cirrhotic patients with hypersplenism and thrombocytopenia, Journal of Gastroenterology and Hepatology, 2012, 27, 2
  41. 41
    Makiko Takeyasu, Norio Akuta, Fumitaka Suzuki, Yuya Seko, Yusuke Kawamura, Hitomi Sezaki, Yoshiyuki Suzuki, Tetsuya Hosaka, Masahiro Kobayashi, Mariko Kobayashi, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada, Long-term interferon monotherapy reduces the risk of HCV-associated hepatocellular carcinoma, Journal of Medical Virology, 2012, 84, 8
  42. 42
    Mark W. Russo, The Role of Interferon Therapy in Patients with Hepatocellular Carcinoma, Current Hepatitis Reports, 2012, 11, 4, 279

    CrossRef

  43. 43
    Yasuhiro Asahina, Namiki Izumi, Makoto Oketani, Hiromitsu Kumada, Kazuhiko Koike, Fumitaka Suzuki, Hajime Takikawa, Atsushi Tanaka, Hirohito Tsubouchi, Norio Hayashi, Naoki Hiramatsu, Hiroshi Yotsuyanagi, Treatment Guidelines of Hepatitis C, Kanzo, 2012, 53, 6, 355

    CrossRef

  44. 44
    Takeo Hayashi, Mosaburo Kainuma, Hiroaki Taniai, Masayuki Murata, Kyoko Okada, Yasunori Sawayama, Norihiro Furusyo, Jun Hayashi, A case of type 1 diabetes mellitus caused by low-dose, long-term natural interferon α therapy for a patient with chronic hepatitis C, Kanzo, 2011, 52, 6, 335

    CrossRef

  45. 45
    Manri Kawakami, Yasuhiro Umekawa, A female patient developing hepatocellular carcinoma 4.5 years after sustained virological response to interferon therapy for chronic hepatitis C: Comparison with cases of male patients, Kanzo, 2011, 52, 11, 722

    CrossRef

  46. 46
    Masakuni Tateyama, Hiroshi Yatsuhashi, Naota Taura, Yasuhide Motoyoshi, Shinya Nagaoka, Kenji Yanagi, Seigo Abiru, Koji Yano, Atsumasa Komori, Kiyoshi Migita, Minoru Nakamura, Hiroyasu Nagahama, Yutaka Sasaki, Yuzo Miyakawa, Hiromi Ishibashi, Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus, Journal of Gastroenterology, 2011, 46, 1, 92

    CrossRef

  47. 47
    Yuko Nagaoki, Hiroshi Aikata, Daisuke Miyaki, Eisuke Murakami, Yoshimasa Hashimoto, Yoshio Katamura, Takahiro Azakami, Tomokazu Kawaoka, Shintaro Takaki, Akira Hiramatsu, Koji Waki, Michio Imamura, Yoshiiku Kawakami, Shoichi Takahashi, Kazuaki Chayama, Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapy, Journal of Gastroenterology, 2011, 46, 6, 799

    CrossRef

  48. 48
    Elena Vezali, Alessio Aghemo, Pietro Lampertico, Massimo Colombo, Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis?, Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 6-7, 455

    CrossRef

  49. 49
    Vivian Ng, Sammy Saab, Effects of a Sustained Virologic Response on Outcomes of Patients With Chronic Hepatitis C, Clinical Gastroenterology and Hepatology, 2011, 9, 11, 923

    CrossRef

  50. 50
    Masatoshi Kudo, Hepatocellular Carcinoma in 2011 and Beyond: From the Pathogenesis to Molecular Targeted Therapy, Oncology, 2011, 81, s1, 1

    CrossRef

  51. 51
    Davendra P. S. Sohal, Weijing Sun, Hepatocellular Carcinoma: Prevention and Therapy, Current Oncology Reports, 2011, 13, 3, 186

    CrossRef

  52. 52
    Seiji Ishiguro, Manami Inoue, Yasuhito Tanaka, Masashi Mizokami, Motoki Iwasaki, Shoichiro Tsugane, Impact of viral load of hepatitis C on the incidence of hepatocellular carcinoma: A population-based cohort study (JPHC Study), Cancer Letters, 2011, 300, 2, 173

    CrossRef

  53. 53
    Tsugiko Oze, Naoki Hiramatsu, Takayuki Yakushijin, Kiyoshi Mochizuki, Masahide Oshita, Hideki Hagiwara, Eiji Mita, Toshifumi Ito, Hiroyuki Fukui, Yoshiaki Inui, Taizo Hijioka, Masami Inada, Kazuhiro Kaytayama, Shinji Tamura, Harumasa Yoshihara, Atsuo Inoue, Yasuharu Imai, Michio Kato, Takuya Miyagi, Yuichi Yoshida, Tomohide Tatsumi, Shinichi Kiso, Tatsuya Kanto, Akinori Kasahara, Tetsuo Takehara, Norio Hayashi, Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy, Journal of Hepatology, 2011, 54, 4, 604

    CrossRef

  54. 54
    Hiroshi Adachi, Katsuhisa Inamura, Toshiyuki Okamura, Tatsuho Sugimoto, The anti-viral effect and the influence on the values of ALT and AFP by low-dose PEG-IFNα2a treatment for prevention of cancer in patients with chronic hepatitis C, Kanzo, 2011, 52, 2, 94

    CrossRef

  55. 55
    Tsugiko Oze, Naoki Hiramatsu, Takayuki Yakushijin, Kiyoshi Mochizuki, Kazuho Imanaka, Akira Yamada, Masahide Oshita, Akira Kaneko, Hideki Hagiwara, Eiji Mita, Toshifumi Ito, Toshihiko Nagase, Yoshiaki Inui, Taizo Hijioka, Shinji Tamura, Harumasa Yoshihara, Eijiro Hayashi, Yasuharu Imai, Michio Kato, Atsushi Hosui, Takuya Miyagi, Yuichi Yoshida, Hisashi Ishida, Tomohide Tatsumi, Shinichi Kiso, Tatsuya Kanto, Akinori Kasahara, Tetsuo Takehara, Norio Hayashi, The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan, Journal of Gastroenterology, 2011, 46, 7, 944

    CrossRef

  56. 56
    Naota Taura, Nobuyoshi Fukushima, Hiroshi Yastuhashi, Yuko Takami, Masataka Seike, Hiroshi Watanabe, Toshihiko Mizuta, Yutaka Sasaki, Kenji Nagata, Akinari Tabara, Yasuji Komorizono, Akinobu Taketomi, Shuichi Matsumoto, Tsutomu Tamai, Toyokichi Muro, Kazuhiko Nakao, Kunitaka Fukuizumi, Tatsuji Maeshiro, Osami Inoue, Michio Sata, The incidence of hepatocellular carcinoma associated with hepatitis C infection decreased in Kyushu area, Medical Science Monitor, 2011, 17, 2, PH7

    CrossRef

  57. 57
    Ryota Higuchi, Hideki Yasuda, Keiji Koda, Masato Suzuki, Masato Yamazaki, Tohru Tezuka, Chihiro Kosugi, Atsushi Hirano, Shuichiro Uemura, Hironori Tsuchiya, Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons), 2011, 36, 1, 66

    CrossRef

  58. 58
    Kenji Ikeda, Masahiro Kobayashi, Yuya Seko, Norihiro Imai, Miharu Hirakawa, Yusuke Kawamura, Hitomi Sezaki, Tetsuya Hosaka, Norio Akuta, Satoshi Saitoh, Fumitaka Suzuki, Yoshiyuki Suzuki, Yasuji Arase, Hiromitsu Kumada, Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation: A retrospective study of hepatitis C virus-related liver cancer, Hepatology Research, 2010, 40, 12
  59. 59
    Masao Omata, Laurentius A. Lesmana, Ryosuke Tateishi, Pei-Jer Chen, Shi-Ming Lin, Haruhiko Yoshida, Masatoshi Kudo, Jeong Min Lee, Byung Ihn Choi, Ronnie T. P. Poon, Shuichiro Shiina, Ann Lii Cheng, Ji-Dong Jia, Shuntaro Obi, Kwang Hyub Han, Wasim Jafri, Pierce Chow, Seng Gee Lim, Yogesh K. Chawla, Unggul Budihusodo, Rino A. Gani, C. Rinaldi Lesmana, Terawan Agus Putranto, Yun Fan Liaw, Shiv Kumar Sarin, Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma, Hepatology International, 2010, 4, 2, 439

    CrossRef

  60. You have free access to this content60
    Chapter 1: Prevention, Hepatology Research, 2010, 40,
  61. 61
    Ryota Masuzaki, Haruhiko Yoshida, Masao Omata, Does chemotherapy prevent HCV-related hepatocellular carcinoma? Pros, Digestive and Liver Disease, 2010, 42, S281

    CrossRef

  62. 62
    Yasuhiro Asahina, Kaoru Tsuchiya, Nobuharu Tamaki, Itsuko Hirayama, Tomohiro Tanaka, Mitsuaki Sato, Yutaka Yasui, Takanori Hosokawa, Ken Ueda, Teiji Kuzuya, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Masayuki Kurosaki, Nobuyuki Enomoto, Namiki Izumi, Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection, Hepatology, 2010, 52, 2
  63. 63
    Yoshito Tomimaru, Hiroaki Nagano, Hidetoshi Eguchi, Shogo Kobayashi, Shigeru Marubashi, Hiroshi Wada, Masahiro Tanemura, Koji Umeshita, Naoki Hiramatsu, Tetsuo Takehara, Yuichiro Doki, Masaki Mori, Effects of preceding interferon therapy on outcome after surgery for hepatitis C virus-related hepatocellular carcinoma, Journal of Surgical Oncology, 2010, 102, 4
  64. 64
    Tomohiko Akahoshi, Morimasa Tomikawa, Daisuke Korenaga, Koji Ikejiri, Motonori Saku, Kenji Takenaka, Laparoscopic splenectomy with peginterferon and ribavirin therapy for patients with hepatitis C virus cirrhosis and hypersplenism, Surgical Endoscopy, 2010, 24, 3, 680

    CrossRef

  65. 65
    Izumi Namiki, Shuhei Nishiguchi, Keisuke Hino, Fumitaka Suzuki, Hiromitsu Kumada, Yoshihito Itoh, Yusuhiro Asahina, Akihiro Tamori, Naoki Hiramatsu, Norio Hayashi, Masatoshi Kudo, Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009), Hepatology Research, 2010, 40, 4
  66. 66
    Timothy R. Morgan, Marc G. Ghany, Hae-Young Kim, Kristin K. Snow, Mitchell L. Shiffman, Jennifer L. De Santo, William M. Lee, Adrian M. Di Bisceglie, Herbert L. Bonkovsky, Jules L. Dienstag, Chihiro Morishima, Karen L. Lindsay, Anna S. F. Lok, Outcome of sustained virological responders with histologically advanced chronic hepatitis C, Hepatology, 2010, 52, 3
  67. You have free access to this content67
    Prevention of hepatocellular carcinoma in the Asia–Pacific region: Consensus statements, Journal of Gastroenterology and Hepatology, 2010, 25, 4
  68. 68
    Y. Imai, S. Tamura, H. Tanaka, N. Hiramatsu, S. Kiso, Y. Doi, M. Inada, T. Nagase, T. Kitada, K. Imanaka, K. Fukuda, T. Takehara, A. Kasahara, N. Hayashi, Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders, Journal of Viral Hepatitis, 2010, 17, 3
  69. 69
    Nadia Bouzgarrou, Elham Hassen, Karim Farhat, Olfa Bahri, Sallouha Gabbouj, Nadia Maamouri, Nabil Ben Mami, Hammouda Saffar, Abdelhalim Trabelsi, Henda Triki, Lotfi Chouchane, Combined analysis of interferon-γ and interleukin-10 gene polymorphisms and chronic hepatitis C severity, Human Immunology, 2009, 70, 4, 230

    CrossRef

  70. 70
    Tsuyoshi Mashitani, Hitoshi Yoshiji, Masaharu Yamazaki, Yasuhide Ikenaka, Ryuichi Noguchi, Masatoshi Ishikawa, Hideto Kawaratani, Norihide Matsuo, Masahito Uemura, Junichi Yamao, Masao Fujimoto, Akira Mitoro, Masahisa Toyohara, Motoyuki Yoshida, Masayoshi Sawai, Chie Morioka, Tatsuhiro Tsujimoto, Mitsuteru Kitade, Kosuke Kaji, Yosuke Aihara, Hiroshi Fukui, Development of hepatocellular carcinoma in a patient 13 years after sustained virological response to interferon against chronic hepatitis C: a case report, Cases Journal, 2009, 2, 1, 18

    CrossRef

  71. 71
    Mika Kurokawa, Naoki Hiramatsu, Tsugiko Oze, Kiyoshi Mochizuki, Takayuki Yakushijin, Nao Kurashige, Yuko Inoue, Takumi Igura, Kazuho Imanaka, Akira Yamada, Masahide Oshita, Hideki Hagiwara, Eiji Mita, Toshifumi Ito, Yoshiaki Inui, Taizo Hijioka, Harumasa Yoshihara, Atsuo Inoue, Yasuharu Imai, Michio Kato, Shinichi Kiso, Tatsuya Kanto, Tetsuo Takehara, Akinori Kasahara, Norio Hayashi, Effect of interferon α-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis, Hepatology Research, 2009, 39, 5
  72. 72
    Takeji Umemura, Tetsuya Ichijo, Kaname Yoshizawa, Eiji Tanaka, Kendo Kiyosawa, Epidemiology of hepatocellular carcinoma in Japan, Journal of Gastroenterology, 2009, 44, S19, 102

    CrossRef

  73. 73
    Mark W. Russo, Erratum to: The Role of Interferon Therapy in Patients With Hepatocellular Carcinoma, Current Hepatitis Reports, 2009, 8, S1, 35

    CrossRef

  74. 74
    Joseph Ahn, Steven L. Flamm, Hepatitis C and hepatocellular carcinoma: New developments in natural history and treatment, Current Hepatitis Reports, 2009, 8, 2, 59

    CrossRef

  75. 75
    Mitsuharu Hanada, Akemi Baba, Yasuyuki Tsutsumishita, Toshihiro Noguchi, Takashi Yamaoka, Nobuyoshi Chiba, Fumio Nishikaku, Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis, Cancer Chemotherapy and Pharmacology, 2009, 64, 3, 473

    CrossRef

  76. 76
    Pierre Nahon, Adrien Kettaneh, Maud Lemoine, Olivier Seror, Nathalie Barget, Jean-Claude Trinchet, Michel Beaugrand, Nathalie Ganne-Carrié, Liver stiffness measurement in patients with cirrhosis and hepatocellular carcinoma: a case–control study, European Journal of Gastroenterology & Hepatology, 2009, 21, 2, 214

    CrossRef

  77. 77
    Kenji Ikeda, Yasuji Arase, Yusuke Kawamura, Hiromi Yatsuji, Hitomi Sezaki, Tetsuya Hosaka, Norio Akuta, Masahiro Kobayashi, Satoshi Saitoh, Fumitaka Suzuki, Yoshiyuki Suzuki, Hiromitsu Kumada, Necessities of Interferon Therapy in Elderly Patients with Chronic Hepatitis C, The American Journal of Medicine, 2009, 122, 5, 479

    CrossRef

  78. 78
    T. Oze, N. Hiramatsu, T. Yakushijin, M. Kurokawa, T. Igura, K. Mochizuki, K. Imanaka, A. Yamada, M. Oshita, H. Hagiwara, E. Mita, T. Ito, Y. Inui, T. Hijioka, S. Tamura, H. Yoshihara, E. Hayashi, A. Inoue, Y. Imai, M. Kato, Y. Yoshida, T. Tatsumi, K. Ohkawa, S. Kiso, T. Kanto, A. Kasahara, T. Takehara, N. Hayashi, Pegylated interferon alpha-2b (Peg-IFN α-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN α-2b plus ribavirin, Journal of Viral Hepatitis, 2009, 16, 8
  79. 79
    Shoji Kubo, Prevention of cancer recurrence after treatment for hepatitis C virus-related hepatocellular carcinoma by interferon therapy, Clinical Journal of Gastroenterology, 2009, 2, 2, 65

    CrossRef

  80. 80
    Yasushi Tamura, Satoshi Yamagiwa, Yohei Aoki, So Kurita, Takeshi Suda, Shogo Ohkoshi, Minoru Nomoto, Yutaka Aoyagi, Serum Alpha-Fetoprotein Levels During and After Interferon Therapy and the Development of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C, Digestive Diseases and Sciences, 2009, 54, 11, 2530

    CrossRef

  81. 81
    Angelo Sangiovanni, Massimo Colombo, Hepatocellular Carcinoma, 2009,

    CrossRef

  82. 82
    Satoshi Katagiri, Yoshihito Kotera, Takahashi Yutaka, Takaaki Kato, Yuusuke Okano, Jun Takasaki, Koichi Kitagawa, Shunichi Ariizumi, Atushi Aruga, Masakazu Yamamoto, Journal of Microwave Surgery, 2009, 27, 39

    CrossRef

  83. 83
    Chiharu Shima, Akira Yamada, Mako Tsubosaka, Motoko Sakurai, Kouji Nakatani, Kazuo Kinoshita, Osamu Kishida, Takashi Fujimoto, Yuzo Minami, A case of chronic hepatitis C with sustained virological response by an intermittent use of low dose pegylated interferon, Kanzo, 2008, 49, 10, 470

    CrossRef

  84. 84
    N. Bouzgarrou, E. Hassen, E. Schvoerer, F. Stoll-Keller, O. Bahri, S. Gabbouj, I. Cheikh, N. Maamouri, N. Mammi, H. Saffar, A. Trabelsi, H. Triki, L. Chouchane, Association of interleukin-18 polymorphisms and plasma level with the outcome of chronic HCV infection, Journal of Medical Virology, 2008, 80, 4
  85. 85
    Maria Pleguezuelo, Laura Marelli, Sergio Maimone, Pinelopi Manousou, Elias Xirouchakis, Andrew K. Burroughs, Does HCV antiviral therapy decrease the risk of hepatocellular carcinoma?, Current Hepatitis Reports, 2008, 7, 2, 72

    CrossRef

  86. 86
    Miharu Hirakawa, Kenji Ikeda, Yasuji Arase, Yusuke Kawamura, Hiromi Yatsuji, Tetsuya Hosaka, Hitomi Sezaki, Norio Akuta, Masahiro Kobayashi, Satoshi Saitoh, Fumitaka Suzuki, Yoshiyuki Suzuki, Hiromitsu Kumada, Hepatocarcinogenesis Following HCV RNA Eradication by Interferon in Chronic Hepatitis Patients, Internal Medicine, 2008, 47, 19, 1637

    CrossRef

  87. 87
    Simon P. Dawson, Hepatocellular carcinoma and the ubiquitin–proteasome system, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2008, 1782, 12, 775

    CrossRef

  88. 88
    Yoshihide Ueda, Yasutsugu Takada, Hironori Haga, Motoshige Nabeshima, Hiroyuki Marusawa, Takashi Ito, Hiroto Egawa, Koichi Tanaka, Shinji Uemoto, Tsutomu Chiba, Limited Benefit of Biochemical Response to Combination Therapy for Patients With Recurrent Hepatitis C After Living-Donor Liver Transplantation, Transplantation, 2008, 85, 6, 855

    CrossRef

  89. 89
    Haruaki Shirakawa, Akihiro Matsumoto, Satoru Joshita, Michiharu Komatsu, Naoki Tanaka, Takeji Umemura, Tetsuya Ichijo, Kaname Yoshizawa, Kendo Kiyosawa, Eiji Tanaka, Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors, Hepatology, 2008, 48, 6
  90. 90
    Takahiro Uenishi, Shuhei Nishiguchi, Shogo Tanaka, Takatsugu Yamamoto, Shigekazu Takemura, Shoji Kubo, Response to interferon therapy affects risk factors for postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma, Journal of Surgical Oncology, 2008, 98, 5
  91. 91
    Shoji Kubo, Shigekazu Takemura, Takahiro Uenishi, Takatsugu Yamamoto, Kazuki Ohba, Masao Ogawa, Seikan Hai, Tsuyoshi Ichikawa, Shintaro Kodai, Hiroji Shinkawa, Hiromu Tanaka, Second Hepatic Resection for Recurrent Hepatocellular Carcinoma in Patients with Chronic Hepatitis C, World Journal of Surgery, 2008, 32, 4, 632

    CrossRef

  92. 92
    Yeon-Joo Kim, Young-Il Kim, Young-A Song, Nam-Cheol Jin, Sung-Ryoun Lim, Dae-Yeul Ryang, Kyoung-Myeun Chung, Seon-Young Park, Chang-Hwan Park, Hyun-Soo Kim, Sung-Kyu Choi, Jong-Sun Rew, The Effectiveness of Combination Therapy with Peginterferon α-2a and Ribavirin in Chronic Hepatitis C, Chonnam Medical Journal, 2008, 44, 2, 72

    CrossRef

  93. 93
    Norio Akuta, Fumitaka Suzuki, Yusuke Kawamura, Hiromi Yatsuji, Hitomi Sezaki, Yoshiyuki Suzuki, Tetsuya Hosaka, Masahiro Kobayashi, Mariko Kobayashi, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada, Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis, Hepatology, 2007, 46, 5
  94. 94
    S. Kobayashi, T. Takeda, M. Enomoto, A. Tamori, N. Kawada, D. Habu, H. Sakaguchi, T. Kuroda, K. Kioka, S. R. Kim, T. Kanno, T. Ueda, M. Hirano, S. Fujimoto, H. Jomura, S. Nishiguchi, S. Seki, Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients, Liver International, 2007, 27, 2
  95. 95
    Hirohisa Yano, Yuji Basaki, Shinji Oie, Sachiko Ogasawara, Seiya Momosaki, Jun Akiba, Naoyo Nishida, Sakiko Kojiro, Hironori Ishizaki, Fukuko Moriya, Keitaro Kuratomi, Suguru Fukahori, Michihiko Kuwano, Masamichi Kojiro, Effects of IFN-αonα-Fetoprotein Expressions in Hepatocellular Carcinoma Cells, Journal of Interferon & Cytokine Research, 2007, 27, 3, 231

    CrossRef

  96. 96
    Hideyuki Nomura, Yoichiro Kashiwagi, Ryouko Hirano, Hironori Tanimoto, Nobuo Tsutsumi, Masashi Higashi, Hiromi Ishibashi, Efficacy of low dose long-term interferon monotherapy in aged patients with chronic hepatitis C genotype 1 and its relation to alpha-fetoprotein: A pilot study, Hepatology Research, 2007, 37, 7
  97. 97
    Takashi Honda, Yoshiaki Katano, Fumihiro Urano, Mutsumi Murayama, Kazuhiko Hayashi, Masatoshi Ishigami, Isao Nakano, Kentaro Yoshioka, Hidenori Toyoda, Takashi Kumada, Hidemi Goto, Efficacy of ribavirin plus interferon-α in patients aged ≥60 years with chronic hepatitis C, Journal of Gastroenterology and Hepatology, 2007, 22, 7
  98. 98
    Takeji Umemura, Kendo Kiyosawa, Epidemiology of hepatocellular carcinoma in Japan, Hepatology Research, 2007, 37,
  99. 99
    Hitomi Sezaki, Fumitaka Suzuki, Yusuke Kawamura, Hiromi Yatsuji, Tetsuya Hosaka, Norio Akuta, Masahiro Kobayashi, Yoshiyuki Suzuki, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada, Evaluation of long-term biochemical responses to combination therapy of interferon plus ribavirin in those infected with hepatitis C virus genotype 1b and high baseline viral load, Hepatology Research, 2007, 37, 10
  100. 100
    Sachiko Ogasawara, Hirohisa Yano, Seiya Momosaki, Jun Akiba, Naoyo Nishida, Sakiko Kojiro, Fukuko Moriya, Hironori Ishizaki, Keitaro Kuratomi, Masamichi Kojiro, Growth Inhibitory Effects of IFN-βon Human Liver Cancer CellsIn VitroandIn Vivo, Journal of Interferon & Cytokine Research, 2007, 27, 6, 507

    CrossRef

  101. 101
    Hashem B. El–Serag, K. Lenhard Rudolph, Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis, Gastroenterology, 2007, 132, 7, 2557

    CrossRef

  102. 102
    Hideaki Taniguchi, Yoshiaki Iwasaki, Akira Takahashi, Hiroyuki Shimomura, Akio Moriya, Piao Cheng Yu, Fumi Umeoka, Shin-ichi Fujioka, Norio Koide, Yasushi Shiratori, Intrahepatic mRNA Levels of Type I Interferon Receptor and Interferon-Stimulated Genes in Genotype 1b Chronic Hepatitis C, Intervirology, 2007, 50, 1, 32

    CrossRef

  103. 103
    Soo R. Kim, Is long-term interferon monotherapy welcome news for older patients with chronic hepatitis C genotype 1?, Hepatology Research, 2007, 37, 7
  104. 104
    Yasuji Arase, Kenji Ikeda, Fumitaka Suzuki, Yoshiyuki Suzuki, Satoshi Saitoh, Masahiro Kobayashi, Norio Akuta, Takashi Someya, Rikako Koyama, Tetsuya Hosaka, Hitomi Sezaki, Mariko Kobayashi, Hiromitsu Kumada, Long-Term Outcome after Interferon Therapy in Elderly Patients with Chronic Hepatitis C, Intervirology, 2007, 50, 1, 16

    CrossRef

  105. 105
    Takashi Iwata, Kiyotoshi Inoue, Noritoshi Nishiyama, Koshi Nagano, Nobuhiro Izumi, Shinjiro Mizuguchi, Ryuhei Morita, Takuma Tsukioka, Shigefumi Suehiro, Long-Term Outcome of Surgical Treatment for Non-Small Cell Lung Cancer With Comorbid Liver Cirrhosis, The Annals of Thoracic Surgery, 2007, 84, 6, 1810

    CrossRef

  106. 106
    Salleh Ibrahim, Anupama Roychowdhury, Tay Khoon Hean, Risk factors for intrahepatic recurrence after hepatectomy for hepatocellular carcinoma, The American Journal of Surgery, 2007, 194, 1, 17

    CrossRef

  107. 107
    Shoji Kubo, Hiromu Tanaka, Shigekazu Takemura, Satoshi Yamamoto, Seikan Hai, Tsuyoshi Ichikawa, Shintaro Kodai, Hiroji Shinkawa, Taichi Shuto, Kazuhiro Hirohashi, Surgical Treatment for Hepatocellular Carcinoma Detected After Successful Interferon Therapy, Surgery Today, 2007, 37, 4, 285

    CrossRef

  108. 108
    Youichi Kawano, Kaku Egami, Koji Sasajima, Masayuki Miyamoto, Tadashi Yokoyama, Shotaro Maeda, Hiroshi Yoshida, Yasuhiro Mamada, Nobuhiko Taniai, Takashi Tajiri, Kanzo, 2007, 48, 2, 48

    CrossRef

  109. 109
    HIDENORI TOYODA, TAKASHI KUMADA, ‘YES, NOW YOU ARE FREE FROM CHRONIC HCV INFECTION, BUT . . .’, Journal of Gastroenterology and Hepatology, 2006, 21, 1
  110. 110
    Kenji Ikeda, Yasuji Arase, Masahiro Kobayashi, Satoshi Saitoh, Takashi Someya, Tetsuya Hosaka, Hitomi Sezaki, Norio Akuta, Yoshiyuki Suzuki, Fumitaka Suzuki, Hiromitsu Kumada, A Long-Term Glycyrrhizin Injection Therapy Reduces Hepatocellular Carcinogenesis Rate in Patients with Interferon-Resistant Active Chronic Hepatitis C: A Cohort Study of 1249 Patients, Digestive Diseases and Sciences, 2006, 51, 3, 603

    CrossRef

  111. 111
    Masahiko Kaito, Shinichiro Horiike, Hideaki Tanaka, Naoki Fujita, Yukihiko Adachi, Accumulation of 8-n itroguanine in the liver of chronic hepatitis C patients without sustained virological response after completion of interferon therapy, Journal of Gastroenterology, 2006, 41, 7, 713

    CrossRef

  112. 112
    Robert Suruki, Katsuhiro Hayashi, Kazunori Kusumoto, Hirofumi Uto, Akio Ido, Hirohito Tsubouchi, Sherri O. Stuver, Alanine aminotransferase level as a predictor of hepatitis C virus-associated hepatocellular carcinoma incidence in a community-based population in Japan, International Journal of Cancer, 2006, 119, 1
  113. 113
    Jules L. Dienstag, John G. McHutchison, American Gastroenterological Association Technical Review on the Management of Hepatitis C, Gastroenterology, 2006, 130, 1, 231

    CrossRef

  114. 114
    Kenji Ikeda, Yasuji Arase, Satoshi Saitoh, Masahiro Kobayashi, Takashi Someya, Tetsuya Hosaka, Hitomi Sezaki, Norio Akuta, Fumitaka Suzuki, Yoshiyuki Suzuki, Hiromitsu Kumada, Anticarcinogenic Impact of Interferon on Patients with Chronic Hepatitis C: A Large-Scale Long-Term Study in a Single Center, Intervirology, 2006, 49, 1-2, 82

    CrossRef

  115. 115
    MASAFUMI IKEDA, SHIGETOSHI FUJIYAMA, MOTOHIKO TANAKA, MICHIO SATA, TATSUYA IDE, HIROSHI YATSUHASHI, HIROSHI WATANABE, Clinical features of hepatocellular carcinoma that occur after sustained virological response to interferon for chronic hepatitis C, Journal of Gastroenterology and Hepatology, 2006, 21, 1
  116. 116
    Ming-Yang Lai, Combined Interferon and Ribavirin Therapy for Chronic Hepatitis C in Taiwan, Intervirology, 2006, 49, 1-2, 91

    CrossRef

  117. 117
    Hellan Kang, Anna S.F. Lok, Endpoints for clinical trials on treatment of hepatitis C, Journal of Hepatology, 2006, 45, 4, 473

    CrossRef

  118. 118
    Hirohisa Yano, Yoshiaki Yanai, Seiya Momosaki, Sachiko Ogasawara, Jun Akiba, Sakiko Kojiro, Fukuko Moriya, Suguru Fukahori, Masashi Kurimoto, Masamichi Kojiro, Growth inhibitory effects of interferon-α subtypes vary according to human liver cancer cell lines, Journal of Gastroenterology and Hepatology, 2006, 21, 11
  119. 119
    Hirohisa Yano, Sachiko Ogasawara, Seiya Momosaki, Jun Akiba, Sakiko Kojiro, Suguru Fukahori, Hironori Ishizaki, Keitaro Kuratomi, Yuji Basaki, Shinji Oie, Michihiko Kuwano, Masamichi Kojiro, Growth inhibitory effects of pegylated IFN α-2b on human liver cancer cells in vitro and in vivo, Liver International, 2006, 26, 8
  120. 120
    John B Wong, Hepatitis C, PharmacoEconomics, 2006, 24, 7, 661

    CrossRef

  121. 121
    Christian Müller, Hepatocellular carcinoma – Rising incidence, changing therapeutic strategies, Wiener Medizinische Wochenschrift, 2006, 156, 13-14, 404

    CrossRef

  122. 122
    Atsushi Sasaki, Yukio Iwashita, Kohei Shibata, Toshifumi Matsumoto, Masayuki Ohta, Seigo Kitano, Improved Long-term Survival after Liver Resection for Hepatocellular Carcinoma in the Modern Era: Retrospective Study from HCV-endemic Areas, World Journal of Surgery, 2006, 30, 8, 1567

    CrossRef

  123. 123
    Stanislas Pol, Vincent O Mallet, Improving anti-hepatitis C virus therapy, Expert Opinion on Biological Therapy, 2006, 6, 9, 923

    CrossRef

  124. You have free access to this content124
    Norio Akuta, Fumitaka Suzuki, Hitomi Sezaki, Yoshiyuki Suzuki, Tetsuya Hosaka, Takashi Someya, Masahiro Kobayashi, Satoshi Saitoh, Sachiyo Watahiki, Junko Sato, Mariko Kobayashi, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada, Predictive factors of virological non-response to interferon–ribavirin combination therapy for patients infected with hepatitis C virus of genotype1b and high viral load, Journal of Medical Virology, 2006, 78, 1
  125. 125
    Masami Asakawa, Hiroshi Kono, Hidetake Amemiya, Masanori Matsuda, Tetsuya Suzuki, Akira Maki, Hideki Fujii, Role of interleukin-18 and its receptor in hepatocellular carcinoma associated with hepatitis C virus infection, International Journal of Cancer, 2006, 118, 3
  126. 126
    Noboru FUJIOKA, Toshio ARIYASU, Norie ARAI, Harumi ARIYASU, Shigeto YAMAMOTO, Tadao TANIMOTO, Hakuo IKEGAMI, Masao IKEDA, Tsunetaka OHTA, Shigeharu FUKUDA, Masashi KURIMOTO, Role of p53 in the inhibitory effects of interferon-α subtypes on proliferation of hepatocellular carcinoma cells, Biomedical Research, 2006, 27, 5, 219

    CrossRef

  127. 127
    Masashi Mizokami, Yasuhito Tanaka, Yuzo Miyakawa, Spread Times of Hepatitis C Virus Estimated by the Molecular Clock Differ among Japan, the United States and Egypt in Reflection of Their Distinct Socioeconomic Backgrounds, Intervirology, 2006, 49, 1-2, 28

    CrossRef

  128. 128
    Masatoshi Akamatsu, Haruhiko Yoshida, Shuichiro Shiina, Takuma Teratani, Shuntaro Obi, Ryousuke Tateishi, Norio Mine, Yuji Kondo, Takao Kawabe, Masao Omata, Sustained viral response prolonged survival of patients with C-viral hepatocellular carcinoma, Liver International, 2006, 26, 5
  129. 129
    Takeshi Okanoue, Akiko Makiyama, Mika Nakayama, Yoshio Sumida, Hironori Mitsuyoshi, Tomoki Nakajima, Kohichiroh Yasui, Masahito Minami, Yoshito Itoh, A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase, Journal of Hepatology, 2005, 43, 4, 599

    CrossRef

  130. 130
    Shinichiro Horiike, Shosuke Kawanishi, Masahiko Kaito, Ning Ma, Hideaki Tanaka, Naoki Fujita, Motoh Iwasa, Yoshinao Kobayashi, Yusuke Hiraku, Shinji Oikawa, Mariko Murata, Jinyan Wang, Reiji Semba, Shozo Watanabe, Yukihiko Adachi, Accumulation of 8-nitroguanine in the liver of patients with chronic hepatitis C, Journal of Hepatology, 2005, 43, 3, 403

    CrossRef

  131. 131
    Norio Akuta, Fumitaka Suzuki, Hitomi Sezaki, Yoshiyuki Suzuki, Tetsuya Hosaka, Takashi Someya, Masahiro Kobayashi, Satoshi Saitoh, Sachiyo Watahiki, Junko Sato, Marie Matsuda, Mariko Kobayashi, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada, Association of Amino Acid Substitution Pattern in Core Protein of Hepatitis C Virus Genotype 1b High Viral Load and Non-Virological Response to Interferon-Ribavirin Combination Therapy, Intervirology, 2005, 48, 6, 372

    CrossRef

  132. 132
    H. Toyoda, T. Kumada, S. Kiriyama, Y. Sone, M. Tanikawa, Y. Hisanaga, T. Kuzuya, T. Honda, K. Hayashi, I. Nakano, Y. Katano, H. Goto, Changes in Hepatitis C Virus (HCV) Antibody Status in Patients with Chronic Hepatitis C after Eradication of HCV Infection by Interferon Therapy, Clinical Infectious Diseases, 2005, 40, 6, e49

    CrossRef

  133. 133
    Y. Tanabe, K. Nagayama, N. Enomoto, N. Izumi, J. Tazawa, M. Kurosaki, N. Sakamoto, C. Sato, M. Watanabe, Characteristic sequence changes of hepatitis C virus genotype 2b associated with sustained biochemical response to IFN therapy, Journal of Viral Hepatitis, 2005, 12, 3
  134. 134
    Adrian M. Di Bisceglie, Patricia Osmack, Elizabeth M. Brunt, Chemoprevention of hepatocellular carcinoma: Use of tamoxifen in an animal model of hepatocarcinogenesis, Journal of Laboratory and Clinical Medicine, 2005, 145, 3, 134

    CrossRef

  135. 135
    Yi-Hsiang Huang, Jaw-Ching Wu, Chien-Hung Chen, Ting-Tsung Chang, Pui-Ching Lee, Gar-Yang Chau, Wing-Yiu Lui, Full-Young Chang, Shou-Dong Lee, Comparison of recurrence after hepatic resection in patients with hepatitis B vs. hepatitis C-related small hepatocellular carcinoma in hepatitis B virus endemic area, Liver International, 2005, 25, 2
  136. 136
    Akihito Tsubota, Yasuji Arase, Takashi Someya, Yoshiyuki Suzuki, Fumitaka Suzuki, Satoshi Saitoh, Kenji Ikeda, Norio Akuta, Tetsuya Hosaka, Masahiro Kobayashi, Hiromitsu Kumada, Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naïve patients infected with hepatitis C virus of genotype 1b and high viral load, Journal of Medical Virology, 2005, 75, 1
  137. 137
    TOSHIO ARIYASU, TAKESHI TANAKA, NOBORU FUJIOKA, YOSHIAKI YANAI, SHIGETO YAMAMOTO, HIROSHI YAMAUCHI, HAKUO IKEGAMI, MASAO IKEDA, MASASHI KURIMOTO, EFFECTS OF INTERFERON-ALPHA SUBTYPES ON THE TH1/TH2 BALANCE IN PERIPHERAL BLOOD MONONUCLEAR CELLS FROM PATIENTS WITH HEPATITIS VIRUS INFECTION–ASSOCIATED LIVER DISORDERS, In Vitro Cellular & Developmental Biology - Animal, 2005, 41, 1, 50

    CrossRef

  138. 138
    Taro Takami, Shuji Terai, Yuichiro Yokoyama, Haruko Tanimoto, Kunihiko Tajima, Koichi Uchida, Takahiro Yamasaki, Isao Sakaida, Hiroshi Nishina, Snorri S. Thorgeirsson, Kiwamu Okita, Human Homologue of Maid Is a Useful Marker Protein in Hepatocarcinogenesis, Gastroenterology, 2005, 128, 5, 1369

    CrossRef

  139. 139
    Yasuhiro Sakaguchi, Masatoshi Kudo, Toyokazu Fukunaga, Yasunori Minami, Hobyung Chung, Toshihiko Kawasaki, Low-Dose, Long-Term, Intermittent Interferon-alpha-2b Therapy after Radical Treatment by Radiofrequency Ablation Delays Clinical Recurrence in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma, Intervirology, 2005, 48, 1, 64

    CrossRef

  140. 140
    Fumio Imazeki, Osamu Yokosuka, Kenichi Fukai, Shigenobu Kawai, Tatsuo Kanda, Hiroshige Kojima, Hiromitsu Saisho, Lower incidence of hepatic failure than hepatocellular carcinoma in Japanese patients with chronic Hepatitis C, Liver International, 2005, 25, 4
  141. 141
    Michael C. KEW, Prevention of hepatocellular carcinoma, HPB, 2005, 7, 1
  142. 142
    Takahiro Ezaki, Toru Ikegami, Takashi Maeda, Tomomi Yamada, Teruyoshi Ishida, Makoto Hashizume, Yoshihiko Maehara, Prognostic value of thymidine phosphorylase activity in liver tissue adjacent to hepatocellular carcinoma, International Journal of Clinical Oncology, 2005, 10, 3, 171

    CrossRef

  143. 143
    HAJIME TOKITA, HIDEO FUKUI, AKIHISA TANAKA, HIROSHI KAMITSUKASA, MICHIYASU YAGURA, HIDEHARU HARADA, HIROAKI OKAMOTO, Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy, Journal of Gastroenterology and Hepatology, 2005, 20, 5
  144. 144
    Akiko Makiyama, Yoshito Itoh, Akinori Kasahara, Yasuharu Imai, Sumio Kawata, Kentaro Yoshioka, Hirohito Tsubouchi, Kendo Kiyosawa, Shinichi Kakumu, Kiwamu Okita, Norio Hayashi, Takeshi Okanoue, Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy, Cancer, 2004, 101, 7
  145. 145
    Y. Takeda, S. Okoshi, K. Suzuki, M. Yano, J. D. Gangemi, G. Jay, H. Asakura, Y. Aoyagi, Effect of interferon α and cell cycle progression on translation mediated by the hepatitis C virus 5′ untranslated region: a study using a transgenic mouse model, Journal of Viral Hepatitis, 2004, 11, 1
  146. 146
    Shirley A. Coverdale, Mahbub H. Khan, Karen Byth, Rita Lin, Martin Weltman, Jacob George, Dev Samarasinghe, Christopher Liddle, James G. Kench, Evelyn Crewe, Geoffrey C. Farrell, Effects of Interferon Treatment Response on Liver Complications of Chronic Hepatitis C: 9-year Follow-Up Study, The American Journal of Gastroenterology, 2004, 99, 4, 636

    CrossRef

  147. 147
    Jessica A. Davila, Robert O. Morgan, Yasser Shaib, Katherine A. McGlynn, Hashem B. El–Serag, Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: A population-based study, Gastroenterology, 2004, 127, 5, 1372

    CrossRef

  148. 148
    Laurie Blendis, Morris Sherman, Hepatocellular Carcinoma, American Journal of Cancer, 2004, 3, 6, 349

    CrossRef

  149. 149
    Giovanna Fattovich, Tommaso Stroffolini, Irene Zagni, Francesco Donato, Hepatocellular carcinoma in cirrhosis: Incidence and risk factors, Gastroenterology, 2004, 127, 5, S35

    CrossRef

  150. 150
    Kendo Kiyosawa, Takeji Umemura, Tetsuya Ichijo, Akihiro Matsumoto, Kaname Yoshizawa, Amal Gad, Eiji Tanaka, Hepatocellular carcinoma: Recent trends in Japan, Gastroenterology, 2004, 127, 5, S17

    CrossRef

  151. 151
    Noboru FUJIOKA, Takeshi TANAKA, Toshio ARIYASU, Yoshiaki YANAI, Shigeto YAMAMOTO, Hiroshi YAMAUCHI, Hakuo IKEGAMI, Masao IKEDA, Kunzo ORITA, Masashi KURIMOTO, In vitro effects of interferon-alpha subtypes on the Th1/Th2 balance in the peripheral blood mononuclear cells from patients with hepatitis C virus infection, Biomedical Research, 2004, 25, 2, 75

    CrossRef

  152. 152
    Masaki Irie, Sadamu Homma, Hideo Komita, Mikio Zeniya, Donald Kufe, Tsuneya Ohno, Gotaro Toda, Inhibition of spontaneous development of liver tumors by inoculation with dendritic cells loaded with hepatocellular carcinoma cells in C3H/HeNCRJ mice, International Journal of Cancer, 2004, 111, 2
  153. 153
    A. Kasahara, H. Tanaka, T. Okanoue, Y. Imai, H. Tsubouchi, K. Yoshioka, S. Kawata, E. Tanaka, K. Hino, K. Hayashi, S. Tamura, Y. Itoh, K. Kiyosawa, S. Kakumu, K. Okita, N. Hayashi, Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death, Journal of Viral Hepatitis, 2004, 11, 2
  154. 154
    Toru Hisaka, Hirohisa Yano, Sachiko Ogasawara, Seiya Momosaki, Naoyo Nishida, Yumi Takemoto, Sakiko Kojiro, Yuno Katafuchi, Masamichi Kojiro, Interferon-αCon1 suppresses proliferation of liver cancer cell lines in vitro and in vivo, Journal of Hepatology, 2004, 41, 5, 782

    CrossRef

  155. 155
    Masatoshi Akamatsu, Haruhiko Yoshida, Shuichiro Shiina, Takuma Teratani, Ryosuke Tateishi, Shuntaro Obi, Shinpei Sato, Yukihiro Koike, Tomonori Fujishima, Takashi Ishikawa, Yasushi Shiratori, Masao Omata, Neither hepatitis C virus genotype nor virus load affects survival of patients with hepatocellular carcinoma, European Journal of Gastroenterology & Hepatology, 2004, 16, 5, 459

    CrossRef

  156. 156
    T. Jake Liang, Theo Heller, Pathogenesis of hepatitis C—associated hepatocellular carcinoma, Gastroenterology, 2004, 127, 5, S62

    CrossRef

  157. 157
    Hideo Tanaka, Hideaki Tsukuma, Hajime Yamano, Akira Oshima, Hirotoshi Shibata, Prospective study on the risk of hepatocellular carcinoma among hepatitis C virus-positive blood donors focusing on demographic factors, alanine aminotransferase level at donation and interaction with hepatitis B virus, International Journal of Cancer, 2004, 112, 6
  158. 158
    Hideyuki Nomura, Suketo Sou, Hironori Tanimoto, Takashi Nagahama, Yoichi Kimura, Jun Hayashi, Hiromi Ishibashi, Seizaburo Kashiwagi, Short-term interferon-alfa therapy for acute hepatitis C: A randomized controlled trial, Hepatology, 2004, 39, 5
  159. 159
    A. Legrand, N. Vadrot, B. Lardeux, A.F. Bringuier, R. Guillot, G. Feldmann, Study of the effects of interferon a on several human hepatoma cell lines: analysis of the signalling pathway of the cytokine and of its effects on apoptosis and cell proliferation, Liver International, 2004, 24, 2
  160. 160
    Beatrice Gerard, Harry Bleiberg, Treatment of hepatocarcinoma, Current Oncology Reports, 2004, 6, 3, 184

    CrossRef

  161. 161
    Kenichiro Kashiwagi, Norihiko Kubo, Hisashi Nakashima, Jun Hayashi, Norihiro Furusyo, Jun Hayashi, Hideyuki Nomura, Seizaburo Kashiwagi, A prospective comparison of the effect of interferon-alpha and interferon-beta treatment in patients with chronic hepatitis C on the incidence of hepatocellular carcinoma development, Journal of Infection and Chemotherapy, 2003, 9, 4, 333

    CrossRef

  162. 162
    Hidenori Toyoda, Takashi Kumada, Kazuhiko Hayashi, Takashi Honda, Kiyoshi Morita, Daisaku Nishimura, Kazumi Imada, Masami Imoto, Yuji Horiguchi, Hiroshi Nakano, Isao Nakano, Yoshihide Fukuda, Characteristics and prognosis of hepatocellular carcinoma detected in sustained responders to interferon therapy for chronic hepatitis C, Cancer Detection and Prevention, 2003, 27, 6, 498

    CrossRef

  163. 163
    Wen-Kai Weng, Shoshana Levy, Hepatitis C Virus (HCV) and Lymphomagenesis, Leukemia & Lymphoma, 2003, 44, 7, 1113

    CrossRef

  164. 164
    TAKESHI OKANOUE, YOSHITO ITOH, Hepatocellular carcinoma in sustained responders of interferon-treated chronic hepatitis C, Journal of Gastroenterology and Hepatology, 2003, 18, 2
  165. 165
    E. Tabor, Interferon for preventing and treating hepatocellular carcinoma associated with the hepatitis B and C viruses, Digestive and Liver Disease, 2003, 35, 5, 297

    CrossRef

  166. 166
    PC Cheow, LLPJ Ooi, Liver Cancer: An Overview, Cancer Reviews: Asia-Pacific, 2003, 01, 02, 297

    CrossRef

  167. 167
    Giorgio Ercolani, Gian Luca Grazi, Matteo Ravaioli, Massimo Del Gaudio, Andrea Gardini, Matteo Cescon, Giovanni Varotti, Francesco Cetta, Antonino Cavallari, Liver Resection for Hepatocellular Carcinoma on Cirrhosis, Annals of Surgery, 2003, 237, 4, 536

    CrossRef

  168. 168
    John F Perry, Simone I Strasser, Jacob George, Geoffrey C Farrell, Geoffrey W McCaughan, Pharmacotherapy of hepatocellular carcinoma, Expert Opinion on Pharmacotherapy, 2003, 4, 12, 2175

    CrossRef

  169. 169
    David E Kaplan, K.Rajender Reddy, Rising incidence of hepatocellular carcinoma: the role of hepatitis B and C; the impact on transplantation and outcomes, Clinics in Liver Disease, 2003, 7, 3, 683

    CrossRef

  170. 170
    Kenta Suzuki, Shogo Ohkoshi, Masahiko Yano, Takafumi Ichida, Mitsuhiro Takimoto, Akira Naitoh, Shigeki Mori, Kojiro Hata, Kentaro Igarashi, Hidenori Hara, Hironobu Ohta, Kenji Soga, Toshiaki Watanabe, Tomoteru Kamimura, Yutaka Aoyagi, Sustained biochemical remission after interferon treatment may closely be related to the end of treatment biochemical response and associated with a lower incidence of hepatocarcinogenesis, Liver International, 2003, 23, 3
  171. 171
    Hiroshi Yotsuyanagi, Yuzo Miyakawa, Shiro Iino, Frontiers in Viral Hepatitis, 2003,

    CrossRef

  172. 172
    Yasushi Shiratori, Haruhiko Yoshida, Masao Omata, Frontiers in Viral Hepatitis, 2003,

    CrossRef

  173. 173
    A Scott Muerhoff, George J. Dawson, Viral Hepatitis: Molecular Biology, Diagnosis, Epidemiology and Control, 2003,

    CrossRef

  174. 174
    Eisuke Adachi, Shin-ichiro Maehara, Eiji Tsujita, Ken-ichi Taguchi, Shin-ichi Aishima, Tatsuya Rikimaru, Yo-ichi Yamashita, Shinji Tanaka, Clinicopathologic risk factors for recurrence after a curative hepatic resection for hepatocellular carcinoma, Surgery, 2002, 131, 1, S148

    CrossRef

  175. 175
    Yujin Hoshida, Yasushi Shiratori, Masao Omata, Cost-effectiveness of adjuvant interferon therapy after surgical resection of Hepatitis C-related hepatocellular carcinoma, Liver, 2002, 22, 6
  176. 176
    Masanori Matsui, Sanae Machida, Teru Itani-Yohda, Toshitaka Akatsuka, Downregulation of the proteasome subunits, transporter, and antigen presentation in hepatocellular carcinoma, and their restoration by interferon-γ, Journal of Gastroenterology and Hepatology, 2002, 17, 8
  177. 177
    A. S. L. Cheng, H. L. Y. Chan, N. W. Y. Leung, C. T. Liew, K. F. To, P. B. S. Lai, J. J. Y. Sung, Expression of cyclooxygenase-2 in chronic hepatitis B and the effects of anti-viral therapy, Alimentary Pharmacology & Therapeutics, 2002, 16, 2
  178. 178
    Hashem B. El-Serag, Hepatocellular carcinoma and hepatitis C in the United States, Hepatology, 2002, 36, S1
  179. 179
    Haruhiko Yoshida, Yasuyuki Arakawa, Michio Sata, Shuhei Nishiguchi, Michitami Yano, Shigetoshi Fujiyama, Gotarou Yamada, Osamu Yokosuka, Yasushi Shiratori, Masao Omata, Interferon therapy prolonged life expectancy among chronic hepatitis C patients, Gastroenterology, 2002, 123, 2, 483

    CrossRef

  180. 180
    Karen L. Lindsay, Introduction to therapy of hepatitis C, Hepatology, 2002, 36, S1
  181. 181
    MASAO OMATA, HARUHIKO YOSHIDA, YASUSHI SHIRATORI, SHUICHIRO SHIINA, Progression from chronic hepatitis to hepatocellular carcinoma: Natural course and treatments, Journal of Gastroenterology and Hepatology, 2002, 17,
  182. 182
    Jose Franco, Kia Saeian, Role of Antiviral Therapy in the Prevention of Hepatocellular Carcinoma, Journal of Vascular and Interventional Radiology, 2002, 13, 9, S191

    CrossRef

  183. 183
    Kazuaki Ohkubo, Yuji Kato, Tatsuki Ichikawa, Yuji Kajiya, Yoshio Takeda, Shinnichirou Higashi, Keisuke Hamasaki, Kazuhiko Nakao, Keisuke Nakata, Katsumi Eguchi, Viral load is a significant prognostic factor for hepatitis B virus-associated hepatocellular carcinoma, Cancer, 2002, 94, 10
  184. 184
    Shuichi Okada, Toshiya Sato, Seiichiro Yamamoto, Adjuvant interferon for hepatocellular carcinoma, Hepatology, 2001, 33, 2
  185. 185
    Masataka Okuno, Soichi Kojima, Hisataka Moriwaki, Chemoprevention of hepatocellular carcinoma: Concept, progress and perspectives, Journal of Gastroenterology and Hepatology, 2001, 16, 12
  186. 186
    G. V. Papatheodoridis, V. C. Papadimitropoulos, S. J. Hadziyannis, Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis, Alimentary Pharmacology & Therapeutics, 2001, 15, 5
  187. 187
    Shoji Kubo, Shuhei Nishiguchi, Kazuhiro Hirohashi, Hiromu Tanaka, Tadashi Tsukamoto, Taichi Shuto, Shigekazu Takemura, Takatsugu Yamamoto, Takashi Ikebe, Kenichi Wakasa, Susumu Shiomi, Hiroaki Kinoshita, Influence of Previous Interferon Therapy on Recurrence after Resection of Hepatitis C Virus-related Hepatocellular Carcinoma, Cancer Science, 2001, 92, 1
  188. 188
    F. Farinati, S. Gianni, M. Franco, Le carcinome hépato-cellulaire, prévention et diagnostic précoce: où en sommes-nous?, Acta Endoscopica, 2001, 31, 4, 515

    CrossRef

  189. 189
    Alvaro Aguayo, Yehuda Z. Patt, LIVER CANCER, Clinics in Liver Disease, 2001, 5, 2, 479

    CrossRef

  190. 190
    Kenji Ikeda, Satoshi Saitoh, Masahiro Kobayashi, Yoshiyuki Suzuki, Fumitaka Suzuki, Akihito Tsubota, Yasuji Arase, Naoya Murashima, Kazuaki Chayama, Hiromitsu Kumada, Long-term interferon therapy for 1 year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: A pilot study, Journal of Gastroenterology and Hepatology, 2001, 16, 4
  191. 191
    Yasushi Shiratori, Haruhiko Yoshida, Masao Omata, Management of hepatocellular carcinoma: advances in diagnosis, treatment and prevention, Expert Review of Anticancer Therapy, 2001, 1, 2, 277

    CrossRef

  192. 192
    Huy A. Nguyen, Samuel B. Ho, Natural history of chronic hepatitis C: Identifying a window of opportunity for intervention, Journal of Laboratory and Clinical Medicine, 2001, 137, 3, 146

    CrossRef

  193. 193
    Huy A. Nguyen, Samuel B. Ho, Natural history of chronic hepatitis C: Identifying a window of opportunity for intervention, Disease-a-Month, 2001, 47, 12, 593

    CrossRef

  194. 194
    M. Hirata, S. M. F. Akbar, N. Horiike, M. Onji, Noninvasive diagnosis of the degree of hepatic fibrosis using ultrasonography in patients with chronic liver disease due to hepatitis C virus, European Journal of Clinical Investigation, 2001, 31, 6
  195. 195
    Alvaro Aguayo, Yehuda Z. Patt, Nonsurgical Treatment of Hepatocellular Carcinoma, Clinics in Liver Disease, 2001, 5, 1, 175

    CrossRef

  196. 196
    Yoshio Aizawa, Yuka Shibamoto, Ichiro Takagi, Mikio Zeniya, Gotaro Toda, Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C, Cancer, 2000, 89, 1
  197. 197
    Claudio Zavaglia, Aldo Airoldi, Giovambattista Pinzello, Antiviral Therapy of HBV- and HCV-induced Liver Cirrhosis, Journal of Clinical Gastroenterology, 2000, 30, 3, 234

    CrossRef

  198. 198
    Kazuyoshi Nagayama, Masayuki Kurosaki, Nobuyuki Enomoto, Yuka Miyasaka, Fumiaki Marumo, Chifumi Sato, Characteristics of hepatitis C viral genome associated with disease progression, Hepatology, 2000, 31, 3
  199. 199
    John B Wong, Gary L Davis, Stephen G Pauker, Cost effectiveness of ribavirin/interferon alfa-2b after interferon relapse in chronic hepatitis C, The American Journal of Medicine, 2000, 108, 5, 366

    CrossRef

  200. 200
    Gary L. Davis, Current therapy for chronic hepatitis C, Gastroenterology, 2000, 118, 2, S104

    CrossRef

  201. 201
    Katalin Jármay, Mónika Gallai, Gizella Karácsony, Zsófia Ozsvár, Zsuzsa Schaff, János Lonovics, Ilona Kovalszky, Decorin and actin expression and distribution in patients with chronic hepatitis C following interferon-alfa-2b treatment, Journal of Hepatology, 2000, 32, 6, 993

    CrossRef

  202. 202
    Hideo Tanaka, Hideaki Tsukuma, Akinori Kasahara, Norio Hayashi, Harumasa Yoshihara, Manabu Masuzawa, Tsutomu Kanda, Tohoru Kashiwagi, Atsuo Inoue, Michio Kato, Akira Oshima, Yoko Kinoshita, Takenobu Kamada, Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: A retrospective cohort study of 738 patients, International Journal of Cancer, 2000, 87, 5
  203. 203
    G.W. McCaughan, A. Zekry, Effects of immunosuppression and organ transplantation on the natural history and immunopathogenesis of hepatitis C virus infection, Transplant Infectious Disease, 2000, 2, 4
  204. 204
    Kunio Okuda, Hepatocellular carcinoma, Journal of Hepatology, 2000, 32, 225

    CrossRef

  205. 205
    John T. Edwards, Graeme A. Macdonald, Hepatocellular carcinoma, Current Opinion in Gastroenterology, 2000, 16, 3, 275

    CrossRef

  206. 206
    M. Ołdakowska-Jedynak, M. Durlik, L. Pa̦czek, B. Zielecka, J. Juskowa, J. Pawlak, K. Zieniewicz, M. Krawczyk, L. Gradowska, M. Lao, Hepatocellular carcinoma development in renal allograft recipients, Transplantation Proceedings, 2000, 32, 6, 1363

    CrossRef

  207. 207
    Massimo Colombo, Hepatocellular carcinoma in patients with HCV, Best Practice & Research Clinical Gastroenterology, 2000, 14, 2, 327

    CrossRef

  208. 208
    Masao Omata, Yasushi Shiratori, Long-term effects of interferon therapy on histology and development of hepatocellular carcinoma in hepatitis C, Journal of Gastroenterology and Hepatology, 2000, 15,
  209. 209
    H. Toyoda, T. Kumada, A. Tokuda, Y. Horiguchi, H. Nakano, T. Honda, S. Nakano, K. Hayashi, Y. Katano, I. Nakano, T. Hayakawa, D. Nishimura, K. Kato, K. Imada, M. Imoto, Y. Fukuda, Long-term follow-up of sustained responders to interferon therapy, in patients with chronic hepatitis C, Journal of Viral Hepatitis, 2000, 7, 6
  210. 210
    Yasushi Shiratori, Masao Omata, Predictors of the efficacy of interferon therapy for patients with chronic hepatitis C before and during therapy: how does this modify the treatment course?, Journal of Gastroenterology and Hepatology, 2000, 15,
  211. 211
    Mitsuo Shimada, Tatsuya Rikimaru, Keishi Sugimachi, Takayuki Hamatsu, Yo-ichi Yamashita, Shin-ichi Aishima, Ken-ichi Taguchi, Shinji Tanaka, Ken Shirabe, Keizo Sugimachi, The importance of hepatic resection for hepatocellular carcinoma originating from nonfibrotic liver11No competing interests declared., Journal of the American College of Surgeons, 2000, 191, 5, 531

    CrossRef

  212. 212
    K. Meijer, W. M. Smid, J. Van Der Meer, Treatment of chronic hepatitis C in haemophilia patients, Haemophilia, 2000, 6, 6
  213. 213
    Adrian M. Di Bisceglie, Hepatitis C, 2000,

    CrossRef

  214. 214
    Geoffrey C Farrell, Hepatocellular carcinoma after sustained response to interferon in non-cirrhotic hepatitis C: Flaws in the cure, or a clue to the flaws?, Journal of Gastroenterology and Hepatology, 1999, 14, 9
  215. 215
    Robert C. Kurtz, Hepatocellular carcinoma and coinfection with hepatitis B and C, Cancer, 1999, 86, 5